Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children

NCT05546502 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1050

Enrollment

INDUSTRY

Sponsor class

Conditions

Vaccine Reaction
Vaccine Adverse Reaction

Interventions

BIOLOGICAL: SARS-CoV-2 Protein Subunit Recombinant Vaccine
BIOLOGICAL: Active Comparator

Sponsor

PT Bio Farma

Collaborators

[object Object]
[object Object]
[object Object]